OBJECTIVES: To investigate the quality of life (QoL) in acromegalic patients in relation to biochemical parameters. DESIGN AND METHODS: Single-center, open label study in 14 acromegalic patients (eight woman and six men, age 33-77 years), with normal serum IGF-I levels during long-term treatment with monthly injections of 20 mg of long-acting octreotide. We investigated which biochemical parameter might reflect optimal QoL, using the SF-36 questionnaire. RESULTS: We observed that six patients had a low QoL score at baseline in the same range as observed in cancer patients. The other eight patients had a normal QoL. GH, IGF-I nor free IGF-I could discriminate these two subgroups at baseline. After skipping one monthly injection, all six subjects with the low QoL escaped in their free IGF-I concentrations. Also total IGF-I concentrations escaped in four of these six. In the subjects with normal QoL, free IGF-I levels remained normal in all, while total IGF-I levels only escaped in one. CONCLUSIONS: This study tells us that the currently used biochemical criteria for disease control in acromegaly might be sufficient in assessing long-term mortality and morbidity, but they are insufficient in addressing the most important parameter from the patient's perspective--QoL.

Additional Metadata
Keywords *Quality of Life, *Severity of Illness Index, Acromegaly/*diagnosis/drug therapy/*psychology, Adult, Aged, Antineoplastic Agents, Hormonal/administration & dosage/adverse effects, Biological Markers, Female, Happiness, Human Growth Hormone/blood, Humans, Insulin-Like Growth Factor Binding Protein 3/blood, Insulin-Like Growth Factor I/*metabolism, Male, Middle aged, Octreotide/administration & dosage/adverse effects, Questionnaires
Persistent URL dx.doi.org/10.1530/eje.1.01838, hdl.handle.net/1765/13707
Journal European Journal of Endocrinology
Citation
Bonapart, I.E, ten Have, S.M.T.H, de Herder, W.W, Erdman, R.A.M, Janssen, J.A.M.J.L, van der Lely, A-J, & van Domburg, R.T. (2005). The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. European Journal of Endocrinology, 152(2), 217–224. doi:10.1530/eje.1.01838